Q-omics provides the consensus-scored PI16 profile across patient tissues and cancer cell-line models. PI16 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PI16 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, PI16 RNA expression shows 21,065 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, BLCA, and LUAD as cancer lineages where PI16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PI16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PI16 survival associations across molecular data types. PI16 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PI16 RNA expression–survival associations across cancer types. High PI16 expression shows unfavorable associations in ACC, KIRP and LGG, but favorable associations in LUAD, KIRC and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PI16 RNA expression.
This table summarizes PI16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in BLCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PI16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PI16 shows lower tumor expression in BLCA, COAD, THCA, KIRC, LUAD and KICH. The BLCA box plot shows higher PI16 RNA expression in normal versus tumor tissue (log2 FC = −8.937, t-test p < 0.001).
This table shows molecular features associated with PI16 in patient tissues and cancer cell lines. In patient samples, PI16 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PI16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
